Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Glucose, Circadian Rhythm, Melatonin, Genes, Light
Interventions: placebo, melatonin, bright light, dim light; Drug · Dietary Supplement · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Dependence
Interventions: Double Placebo, Aripiprazole 15, placebo, Aripiprazole 7.5, Placebo, Topiramate 100, Placebo, Topiramate 200, Placebo, Topiramate 100, Aripiprazole 15, Topiramate 100, Aripiprazole 7.5, Topiramate 100, Aripiprazole 15mg, Topiramate 200, Aripiprazole 7.5mg, Topiramate 200, Aripiprazole 15; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions: SEL, FIR, CILO, FENO, VAS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more

Conditions: Hypertriglyceridemia
Interventions: Simvastatin, acetylsalicylic acid (ASA), omefas; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Age-related Macular Degeneration
Interventions: QA102, Placebo; Drug
Lead sponsor: Smilebiotek Zhuhai Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Embibatinib, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine; Drug
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Healthy
Interventions: Chamomile Tea, Parsley based drink, Parsley Yogurt, Apigenin, Parsley-based drink (II); Other
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 60 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Davis, California

Conditions: Cocaine Dependence
Interventions: Doxazosin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: MN-166; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: IPI-145, Midazolam; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: HIV Infections
Interventions: Atazanavir + Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Autism
Interventions: Memantine - Extended Release (ER), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more

Conditions: COVID-19 Infection
Interventions: Brequinar, Placebo; Drug
Lead sponsor: Clear Creek Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more

Conditions: Bipolar Disorder, Bipolar Depression
Interventions: N-acetylcysteine, Minocycline, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastrointestinal Symptoms, Constipation, Gut Health, Gastrointestinal Function
Interventions: Weizmannia (Bacillus) coagulans JBI-YZ6.3, Placebo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Spinal Cord Injury
Interventions: Tiotropium Bromide, Placebo; Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Palbociclib Alone, Palbociclib plus itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lymphoma
Interventions: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years to 60 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Zanubrutinib, Bendamustine, Rituximab, Venetoclax; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 18
States / cities: Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more

Conditions: Metabolic Syndrome
Interventions: Berberine, Identical Placebo; Dietary Supplement · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Neoplasms
Interventions: Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 63
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 38 more

Conditions: Ulcerative Colitis, Ileal Pouch
Interventions: Aquamin; Drug
Lead sponsor: Muhammad N Aslam, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Postoperative Pain
Interventions: Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride); Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 8 more

Conditions: Type 2 Diabetes Mellitus
Interventions: MBX-2044, Placebo for MBX-2044; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Interaction of Melatonin With MTNR1B Genotype on Glucose Control - Study 2

Aripiprazole and Topiramate on Free-Choice Alcohol Use

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)

Absorption, Metabolism and Excretion of Apigenin and Apigenin Glycosides

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam

Bioequivalence Study of Atazanavir 300 mg Capsule

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes

24hr Effects of Tiotropium Bromide in Tetraplegia

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes